Obsessive-compulsive Disorder
📧 Sign up to get email alerts when something new happens for Obsessive-compulsive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-08-18FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)
The FDA approved a supplemental application for paroxetine submitted by Padagis US LLC. This action represents an additional regulatory appr…
-
FDA approval · 2023-08-18FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approves a supplemental application for fluvoxamine maleate submitted by ANI Pharmaceuticals, Inc.
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine hydrochloride from Alembic Pharmaceuticals Limited.
-
FDA approval · 2023-08-10FDA Approved: FLUOXETINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine from Torrent Pharmaceuticals Limited, enabling the generic antidepressant to be manuf…
-
FDA approval · 2023-03-31FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for Granules Pharmaceuticals' sertraline hydrochloride generic product, enabling its marketing in th…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-03-23FDA Approved: PAROXETINE — Supplemental Application (Modavar Pharmaceuticals LLC)
FDA approved a supplemental application for generic paroxetine filed by Modavar Pharmaceuticals LLC under ANDA212645.
-
FDA approval · 2023-03-20FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Original Application (Aurobindo Pharma Limited)
FDA approved the original abbreviated new drug application for clomipramine hydrochloride (generic) by Aurobindo Pharma Limited.
-
FDA approval · 2023-01-31FDA Approved: PAROXETINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for paroxetine from ANI Pharmaceuticals, indicating an approved change to the product (e.g., lab…
-
FDA approval · 2023-01-25FDA Approved: ZOLOFT — Supplemental Application (ROERIG)
The FDA approved a supplemental application for Zoloft (sertraline hydrochloride) filed by Roerig.
-
FDA approval · 2022-12-19FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Apotex Corp)
FDA approved Apotex Corp's supplemental application for fluvoxamine maleate, i.e., the generic fluvoxamine product.
-
FDA approval · 2022-12-05FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA has approved Lupin Pharmaceuticals' supplemental application for sertraline hydrochloride, allowing the generic to be marketed as part o…
-
FDA approval · 2022-11-29FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for escitalopram oxalate (a generic version of Lexapro), enabling market entry…
-
FDA approval · 2022-11-15FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (Upsher-Smith Laboratories, LLC)
The FDA approved Upsher-Smith's fluoxetine hydrochloride as an original generic application, allowing the generic product to be marketed wit…
-
FDA approval · 2022-11-09FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (ANI Pharmaceuticals, Inc.)
FDA approves ANI Pharmaceuticals' original application for fluoxetine hydrochloride, a generic version of fluoxetine.
-
FDA approval · 2022-09-20FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application from ANI Pharmaceuticals for fluvoxamine maleate, corresponding to a modification/expansion of t…
-
FDA approval · 2022-08-30FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for sertraline hydrochloride as a generic, confirming approval under the ANDA p…
-
FDA approval · 2022-03-29FDA Approved: FLUOXETINE — Original Application (Micro Labs Limited)
The FDA approved Micro Labs Limited's original application for a generic fluoxetine product.
-
FDA approval · 2022-02-25FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for paroxetine hydrochloride from Zydus Lifesciences Limited, applying to the generic product.
-
FDA approval · 2022-01-19FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
The FDA granted a supplemental approval for paroxetine hydrochloride (paroxetine) from NorthStar Rx LLC under an ANDA. This approval confirm…
-
FDA approval · 2021-11-02FDA Approved: PAROXETINE — Original Application (Chartwell RX, LLC.)
FDA approved a generic paroxetine product under an original ANDA submitted by Chartwell RX, LLC.
-
FDA approval · 2021-10-04FDA Approved: SERTRALINE HYDROCHLORIDE — Original Application (Alvogen, Inc.)
FDA approves the sertraline hydrochloride generic under an Original Application filed by Alvogen, Inc. The approval enables marketing of a g…
-
FDA approval · 2021-09-21FDA Approved: FLUOXETINE — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for Fluoxetine Hydrochloride from Lannett Company, Inc., a generic fluoxetine product.
-
FDA approval · 2021-09-21FDA Approved: FLUOXETINE — Supplemental Application (Chartwell Governmental & Specialty RX, LLC)
FDA approved a supplemental application for fluoxetine submitted by Chartwell Governmental & Specialty RX, LLC.
-
FDA approval · 2021-09-21FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for fluoxetine hydrochloride submitted by PAI Holdings, LLC dba PAI Pharma. The approval updates the…
-
FDA approval · 2021-09-21FDA Approved: FLUOXETINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine submitted by Torrent Pharmaceuticals Limited.